 "Pharma packaging image via Shutterstock.")
Allergan Plc has acquired Zeltiq Aesthetics Inc, a medical technology company focused on developing and commercialising products utilising its proprietary controlled-cooling technology platform, for $ 2.475 billion.
The acquisition of Zeltiq will enhance Allergan’s global medical aesthetics portfolio with the addition of Zeltiq’s flagship CoolSculpting system, the sales leader in the fast-growing cash pay body contouring segment of medical aesthetics. The CoolSculpting system is FDA-cleared to affect appearance through lipolysis or reduction of unwanted fat using a patented cooling technology. CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without
